Genelux (GNLX) Interest Expenses (2022 - 2026)
Genelux (GNLX) posted quarterly Interest Expenses of $336000.0 for Q1 2026, up 314.81% year-over-year from $81000.0 in Q1 2025, and down 94.27% quarter-over-quarter from $5.9 million in Q4 2025.
Genelux (GNLX) Interest Expenses (2022 - 2026) Analysis & Trends
Genelux's Interest Expenses history runs 5 years deep, the most recent figure standing at $336000.0 for Q1 2026.
- In Q1 2026, Interest Expenses rose 314.81% year-over-year to $336000.0; the TTM figure through Mar 2026 stood at $336000.0 (up 269.7% YoY), while the FY2025 annual figure was $78.5 million, up 29.32% from the prior year.
- Interest Expenses for Q1 2026 stood at $336000.0, down from $5.9 million in the prior quarter.
- The five-year high for Interest Expenses was $111.8 million in Q2 2023, with the low at -$359000.0 in Q4 2023.
- The 5-year median for Interest Expenses is $336000.0 (2026), against an average of $13.4 million.
- Peak annual rise in Interest Expenses reached 25577.62% in 2023, while the deepest fall reached 1789.47% in 2023.
- Genelux's Interest Expenses stood at -$19000.0 in 2022, then tumbled by 1789.47% to -$359000.0 in 2023, then soared by 75.49% to -$88000.0 in 2024, then jumped by 6762.5% to $5.9 million in 2025, then tumbled by 94.27% to $336000.0 in 2026.
- Business Quant data shows GNLX's Interest Expenses at $336000.0 in Q1 2026, $5.9 million in Q4 2025, and $3.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Genelux | 119.87 Mn | 119.87 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 336,000.00 |
| Mar 31, 2026 | 336,000.00 |
| Dec 31, 2025 | 5.86 Mn |
| Dec 31, 2025 | 5.86 Mn |
| Sep 30, 2025 | 3.26 Mn |
| Sep 30, 2025 | 3.26 Mn |
| Jun 30, 2025 | 493,000.00 |
| Jun 30, 2025 | 493,000.00 |
| Mar 31, 2025 | 81,000.00 |
| Mar 31, 2025 | 81,000.00 |
| Dec 31, 2024 | -88,000.00 |
| Dec 31, 2024 | -88,000.00 |
| Sep 30, 2024 | 168,000.00 |
| Sep 30, 2024 | 168,000.00 |
| Mar 31, 2024 | 1.65 Mn |
| Mar 31, 2024 | 1.65 Mn |
| Dec 31, 2023 | -359,000.00 |
| Dec 31, 2023 | -359,000.00 |
| Sep 30, 2023 | 73.44 Mn |
| Sep 30, 2023 | 73.44 Mn |